{"id":35999,"date":"2025-06-25T15:51:41","date_gmt":"2025-06-25T07:51:41","guid":{"rendered":"https:\/\/flcube.com\/?p=35999"},"modified":"2025-06-25T15:51:42","modified_gmt":"2025-06-25T07:51:42","slug":"lundbecks-lu-ag13909-wins-orphan-drug-designations-for-congenital-adrenal-hyperplasia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35999","title":{"rendered":"Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia"},"content":{"rendered":"\n

Denmark-based pharmaceutical company Lundbeck A\/S (OTCMKTS: HLUBF<\/a>) announced that it has received Orphan Drug Designations (ODDs) from the US FDA in May and the European Medicine Agency (EMA) in June for its investigational drug Lu AG13909. The designations are for the treatment of congenital adrenal hyperplasia (CAH).<\/p>\n\n\n\n

Drug Mechanism<\/strong>
Lu AG13909 is a humanized anti-ACTH monoclonal antibody (mAb) that binds with high affinity to adrenocorticotropic hormone (ACTH). By blocking ACTH’s interaction with the melanocortin 2 receptor (MC2R) in the adrenal glands, it suppresses ACTH-driven neurohormonal signaling, leading to reduced secretion of glucocorticoids, mineralocorticoids, and androgens.<\/p>\n\n\n\n

Clinical Trial Progress<\/strong>
The drug is currently being evaluated in an open-label Phase I\/II study in adults (18-70 years) with classic CAH. The trial will be conducted across seven countries\/regions in North America and Europe, with the first batch of sites scheduled to open by the end of June 2025. Participants will receive intravenous medication every month and undergo an extension period evaluation of up to 12 months.<\/p>\n\n\n\n

Safety Profile<\/strong>
Preclinical studies have shown that continuous administration of Lu AG13909 for six months resulted in no toxic reactions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Denmark-based pharmaceutical company Lundbeck A\/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations…<\/p>\n","protected":false},"author":1,"featured_media":36000,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1581,2804,15,24],"class_list":["post-35999","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-h-lundbeck","tag-otcmkts-hlubf","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"\nLundbeck's Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Denmark-based pharmaceutical company Lundbeck A\/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations (ODDs) from the US FDA in May and the European Medicine Agency (EMA) in June for its investigational drug Lu AG13909. The designations are for the treatment of congenital adrenal hyperplasia (CAH).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35999\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lundbeck's Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia\" \/>\n<meta property=\"og:description\" content=\"Denmark-based pharmaceutical company Lundbeck A\/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations (ODDs) from the US FDA in May and the European Medicine Agency (EMA) in June for its investigational drug Lu AG13909. The designations are for the treatment of congenital adrenal hyperplasia (CAH).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35999\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-25T07:51:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-25T07:51:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2509.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia\",\"datePublished\":\"2025-06-25T07:51:41+00:00\",\"dateModified\":\"2025-06-25T07:51:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999\"},\"wordCount\":201,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2509.webp\",\"keywords\":[\"H. Lundbeck\",\"OTCMKTS: HLUBF\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35999#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35999\",\"name\":\"Lundbeck's Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2509.webp\",\"datePublished\":\"2025-06-25T07:51:41+00:00\",\"dateModified\":\"2025-06-25T07:51:42+00:00\",\"description\":\"Denmark-based pharmaceutical company Lundbeck A\\\/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations (ODDs) from the US FDA in May and the European Medicine Agency (EMA) in June for its investigational drug Lu AG13909. The designations are for the treatment of congenital adrenal hyperplasia (CAH).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35999\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2509.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2509.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lundbeck's Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35999#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lundbeck's Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia - Insight, China's Pharmaceutical Industry","description":"Denmark-based pharmaceutical company Lundbeck A\/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations (ODDs) from the US FDA in May and the European Medicine Agency (EMA) in June for its investigational drug Lu AG13909. The designations are for the treatment of congenital adrenal hyperplasia (CAH).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35999","og_locale":"en_US","og_type":"article","og_title":"Lundbeck's Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia","og_description":"Denmark-based pharmaceutical company Lundbeck A\/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations (ODDs) from the US FDA in May and the European Medicine Agency (EMA) in June for its investigational drug Lu AG13909. The designations are for the treatment of congenital adrenal hyperplasia (CAH).","og_url":"https:\/\/flcube.com\/?p=35999","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-25T07:51:41+00:00","article_modified_time":"2025-06-25T07:51:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2509.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35999#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35999"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia","datePublished":"2025-06-25T07:51:41+00:00","dateModified":"2025-06-25T07:51:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35999"},"wordCount":201,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35999#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2509.webp","keywords":["H. Lundbeck","OTCMKTS: HLUBF","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35999#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35999","url":"https:\/\/flcube.com\/?p=35999","name":"Lundbeck's Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35999#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35999#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2509.webp","datePublished":"2025-06-25T07:51:41+00:00","dateModified":"2025-06-25T07:51:42+00:00","description":"Denmark-based pharmaceutical company Lundbeck A\/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations (ODDs) from the US FDA in May and the European Medicine Agency (EMA) in June for its investigational drug Lu AG13909. The designations are for the treatment of congenital adrenal hyperplasia (CAH).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35999#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35999"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35999#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2509.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2509.webp","width":1080,"height":608,"caption":"Lundbeck's Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35999#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2509.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35999"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35999\/revisions"}],"predecessor-version":[{"id":36001,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35999\/revisions\/36001"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36000"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}